Last reviewed · How we verify
High dose losartan
High dose losartan is a Angiotensin II receptor blocker (ARB) Small molecule drug developed by Baker Heart and Diabetes Institute. It is currently FDA-approved for Hypertension, Heart failure, Diabetic nephropathy. Also known as: Losartan (Cozaar).
High-dose losartan blocks angiotensin II type 1 receptors to reduce blood pressure and provide cardiovascular protection.
High-dose losartan blocks angiotensin II type 1 receptors to reduce blood pressure and provide cardiovascular protection. Used for Hypertension, Heart failure, Diabetic nephropathy.
At a glance
| Generic name | High dose losartan |
|---|---|
| Also known as | Losartan (Cozaar) |
| Sponsor | Baker Heart and Diabetes Institute |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, preventing angiotensin II-mediated vasoconstriction, aldosterone release, and sympathetic activation. At higher doses, it provides enhanced blood pressure reduction and may offer additional cardioprotective and renoprotective benefits beyond standard dosing.
Approved indications
- Hypertension
- Heart failure
- Diabetic nephropathy
- Post-myocardial infarction cardioprotection
Common side effects
- Hyperkalemia
- Dizziness
- Fatigue
- Hypotension
- Cough
Key clinical trials
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- The COVID-RASi Trial (COVID-19) (PHASE3)
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. (PHASE4)
- An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension (PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352) (PHASE3)
- Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High dose losartan CI brief — competitive landscape report
- High dose losartan updates RSS · CI watch RSS
- Baker Heart and Diabetes Institute portfolio CI
Frequently asked questions about High dose losartan
What is High dose losartan?
How does High dose losartan work?
What is High dose losartan used for?
Who makes High dose losartan?
Is High dose losartan also known as anything else?
What drug class is High dose losartan in?
What development phase is High dose losartan in?
What are the side effects of High dose losartan?
What does High dose losartan target?
Related
- Drug class: All Angiotensin II receptor blocker (ARB) drugs
- Target: All drugs targeting AT1 receptor (Angiotensin II type 1 receptor)
- Manufacturer: Baker Heart and Diabetes Institute — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Heart failure
- Indication: Drugs for Diabetic nephropathy
- Also known as: Losartan (Cozaar)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing